|Bid||1.2400 x 2200|
|Ask||1.2500 x 3100|
|Day's range||1.1800 - 1.2600|
|52-week range||1.1400 - 5.6000|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
If you love investing in businesses that are on the bleeding edge of biotechnology, psychedelics companies are right up your alley. Despite substantial cultural baggage and significant legal hurdles, psychedelic medicines are proving themselves to be highly effective at treating mental illnesses like depression and post-traumatic stress disorder (PTSD), and that means they're likely to be quite lucrative for the developers. On July 13, the Drug Enforcement Agency (DEA) said it was scheduling a public hearing for Aug. 22, so people would have a chance to comment on a proposed rule that would move five psychedelic compounds into the Schedule 1 category.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...